EUVIMEDEUVIMED entdecken
Open Access

Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept

Ojas Srivastava, Ezekiel Weis

Ocular Oncology and Pathology · 2022 · 8 (4-6) · 230-235

DOI: 10.1159/000526548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ocular Oncology and Pathology, online erschienen am 01.09.2022. Verfasst von Ojas Srivastava und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Radiation retinopathy is a dose-dependent complication of the retina following exposure to ionizing radiation. The objective of this prospective case series is to determine the clinical efficacy of intravitreal aflibercept for radiation retinopathy secondary to radiotherapy for uveal melanoma in those that failed intravitreal bevacizumab treatment.

Methods

A case series of 30 patients with a mean age of 57 ± 15 years with radiation retinopathy were enrolled. Visual acuity (VA) and central foveal thickness (CFT) responses to therapy were assessed with regression analyses at 1 month, 3 months, and 6 months following the switch to aflibercept.

Results

Regression analyses showed a statistically significant reduction in CFT and improvements in VA following the switch to treatment by aflibercept at 1 month, 3 months, and 6 months. The mean CFT improved from 476 μm ± 170 to 386 μm ± 139 and the mean VA improved minimally from 20/115 ± 20/63 to 20/112 ± 20/54 over 6 months. After 6 months of aflibercept, 46% of patients displayed a CFT improvement of 100 μm or greater and 23% of patients showed improvement in VA of 1 line or better.

Conclusion

This pilot study suggests that patients with radiation retinopathy who have failed monthly intravitreal bevacizumab may respond to aflibercept.

Schlagwörter

Stichwörter der Autor:innen

AfliberceptAnti-vascular endothelial growth factorBevacizumabRadiation retinopathyUveal melanoma

Autor:innen und Institutionen

  • Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Ophthalmology, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Surgery, University of Calgary, Calgary, Alberta, Canada.

Zitieren

APA

Srivastava, O., & Weis, E. (2022). Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept. Ocular Oncology and Pathology, 8(4-6), 230-235. https://doi.org/10.1159/000526548

Vancouver

Srivastava O, Weis E. Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept. Ocular Oncology and Pathology. 2022;8(4-6):230-235. doi:10.1159/000526548

BibTeX
@article{Srivastava2022,
  author = {Srivastava, Ojas and Weis, Ezekiel},
  title = {Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept},
  journal = {Ocular Oncology and Pathology},
  year = {2022},
  volume = {8},
  number = {4-6},
  pages = {230--235},
  doi = {10.1159/000526548}
}
Kostenlos starten →